Patent intelligence · EP
EP 2952200
Allergen zur vorbeugenden Behandlung von Allergien
Allergen zur vorbeugenden Behandlung von Allergien
Patent details — EP 2952200
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Dec 9, 2015
- Expiration
- Dec 4, 2035
- Applicant
- ALK ABELLÓ AS [DK]
- CPC classes
- A61K 36/ 899 A I, A61K/3520, A61K/3536, A61K/3557
Quick answer
EP 2952200 (Allergen zur vorbeugenden Behandlung von Allergien) is held by ALK ABELLÓ AS [DK]. Status: granted. Granted Dec 9, 2015. Expires Dec 4, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALK ABELLÓ AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 36/ 899 A I, A61K/3520, A61K/3536, A61K/3557, A61K/3628, A61K/3649
More from ALK ABELLÓ AS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2024200854
ANTICORPS DE LIAISON AUX ALLERGÈNES APPROPRIÉS POUR TRAITER DES ALLERGIES AU POLLEN D'ARBRE
granted -
EP 4302751
ORALE DÜNNFILME MIT GERINGER WASSERAKTIVITÄT
granted -
EP 4302750
ORALE DÜNNFILME ENTHALTEND ADRENALIN
granted -
CA 3259886
DISPOSITIFS DE DÉPLACEMENT D'IGE-FCERI
granted -
WO 2023232958
INHIBITEURS DE LA KINASE DE BRUTON POUR LE TRAITEMENT D'UNE RÉACTION ALLERGIQUE SOUDAINE
granted -
CA 3255134
COMPOSITION D'ALLERGÈNE D'ARACHIDE
granted -
WO 2019224246
MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE
granted -
HK 1249412
PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF
granted
Frequently asked questions
What is US patent 2952200?
EP 2952200 (Allergen zur vorbeugenden Behandlung von Allergien) is held by ALK ABELLÓ AS [DK]. Status: granted. Granted Dec 9, 2015. Expires Dec 4, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2952200?
ALK ABELLÓ AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2952200 expire?
Our index shows an expiration date of Dec 4, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.